I was just saying that I think my 3 elderly cats are much perkier since starting on rapa
Well, one cat just attacked another one, ripping out hair and causing a lot of bleeding. This has never happened in 17 years. It then dawned on me you mentioned your dog become more aggressive. Now I wonder if it’s related. Sigh.
Has anyone heard of this happening in the dog study?
In Kaeberlein’s study only non-reactive dogs are for candidates for the trial.
I am using rapamycin for my companion animal in coordination with a veterinarian who is, himself, a researcher and has experience with rapamycin. Again, if you do not have access to this type of veterinary care locally, you might want to consider PetSpan. You can see Dan’s comments above.
Kelsey, I really appreciate your concern, that is very kind of you. Thank you for making sure my cats have good care. Because you’ve shown your concern twice, I’ll share that I am fortunate to have one of the top IM vets in NorCal, and she is familiar with rapamycin.
I am simply on here just to share information and ask questions, similar to what many forum members do, even those who are fortunate enough to have excellent doctors who give great advice on rapamycin.
It might wind up being helpful for those who see something unexpected, like the incident today from a very mild mannered cat, to share it here incase we eventually see a trend. That is why I was curious if anyone knew if it happened in the dog study. If anyone has heard, do let me know because one incident at my house after 17 years does not show any sort of connection. It’s just a wonder at this point. Thanks
So article got me thinking… dogs can sense disease like cancers.
The several dogs that I helped get on rapamycin have truly shown reversal in health and activity. They are reinvested in activities… sniffing… their best sense and acting years younger. Dry scabbed noses return to healthy wetness. Cancer lumps disapate. They seem truly thankful to their owners.
If they can smell disease in humans… I am guessing they smell their own return to health.
Dog Owners using Rapamycin - please contact me (via Direct message - click on my avatar and then “message” me) if this is potentially of interest. My dog is too young. I think the best person would be a person who has been giving rapamycin to an older dog for at least a year and has some positive results that they can report.
Ideally the person would be in Seattle area, but if not, then the NY area, or other major city (I suspect) - but they are willing to travel, so just include your location in your email to me and I’ll let them figure out the best fit for their needs.
My name is Koji Hayasaki, and I am a TV documentary coordinator based in
New York. I am currently working with NHK, Japan’s public television
broadcaster, on a special documentary focused on anti-aging.
I am trying to follow up my initial inquiry email on May 7th.
This program will explore the latest advancements in anti-aging research
and technology, featuring the work of scientists and entrepreneurs
leading the field. One segment will focus on the science and effects of
rapamycin, including a feature on the Dog Aging Project at Washington
University. As part of this, we will be interviewing Dr. Matt Kaeberlein.
To help our audience better understand the potential health benefits of
rapamycin for dogs, we would like to feature a real-life example of a
dog whose health has improved after taking the drug. I came across
Rapamycin News and a thread discussing dogs’ use of rapamycin:
I’m reaching out to ask whether the NHK team could film you and your dog
for this segment, and if you’d be willing to share your experience. We
plan to film in the U.S. between late August and September, and NHK
would be able to offer compensation for your time.
Thank you very much for considering this opportunity. I look forward to
hearing from you.
I bought rapamycin from a lab, 99.5% purity for animal use.
I’m currently giving 0.75 or 1mg rapa to my 10kg 7.5-years-old dog biweekly.
Have used for 4 month.
Haven’t seen any difference yet, but he does look more energetic.
Are there any test that can do to dog to check if there is any antiaging effect?
Unfortunately there are no tests for anti-aging effects yet (not really in humans either)… so we’re all in the dark.
How are you giving the rapamycin powder to the dog (is it in an enteric encapsulated capsule?). I ask because rapamycin as a powder is not very bioavailable and almost all of it gets destroyed in the gut if its not protected. (standard capsules don’t work). See these threads:
For now I can only buy rapa in powder form, so I could only give it to my dog with food.
Bioavailability is a big problem, but I do find Sirolimus Oral Solution which is in liquid form, clinically it is effective too.
I don’t know if it is OK to increase dose to offset the loss in stomach.
Yes - it would definitely be advised to increase dose based on stomach loss… at least triple the dose because I think the bioavailability is only 1/3 or lower of the protected rapamycin.
Thank you Beth
I tried enteric capsules or other similar container for my dog once, but my dog is not a really big one so he would chew and probably break the capsule before swallow it
So difficult to make him eat meds.
What’s more in my place, sirolimus in tablets form is much much more expensive than powder form
That all makes sense. I guess this means you are not in the US, if you are, let me know and I’ll tell you how to get it cheaper.
Have you ever tried pilling him? (With your homemade capsules)
I have two cats I can pill. It would be too traumatic for my third cat, so unless something was life saving, it wouldn’t do that to him.
I’m happy to do a FaceTime and teach you how to pill him if you think that would help (you buy a little cheap tool and approach from behind and go in the side of his mouth, so he never sees it coming). I just taught a fried how to pill their cat last week and their jaw was on the floor over how quick and easy it was.
FWIW I give rapa to my dog in tablet form (enteric coated) buried in a small chunk of cheese. She eats it so quickly I don’t thing she crunches the tablet (I don’t hear a crunch).
hello everyone I am in the U.K. I have a 13 year old Italian greyhound who weighs 6.5 kgs and we have been having significant issues with him in the last few months. He has two degenerative discs which are causing him no end of issues and I am keen to start him on rapamycin could anyone advise me on where is best to get the tablets what brand of tablets and the dose/dosing regime
It’s so easy to give a pill to a dog if you know the technique. Make your dog sit, open her/his mouth, put pill on the base of tongue, close the mouth and while holding it closed rub the dog’s under the chin area downward. It promotes swallowing. Works with any dog, any size.
I’m not in the UK, but generally it’s harder to get rapamycin (sirolimus) in the UK than in the US or India, etc. Here are some links for sources and approaches to getting rapamycin:
Started our rapamycin this past Saturday and we gave it to our 3 pups as well. My wife and myself started out on 3 mg each. I only ordered 1g tablets and 3 mg tablets. I gave our 3 year old 15 lb female chihuahua 1 mg, our 10 year old 50 lb female pit bull 3 mg, and our 9 year old 75 lb male pit bull 3 mg. Should I lower the does on the first 2 females to half a mg and 2 mg?
Just like for a human, I would start them out on lower doses and ramp up.
I’d also not start the male on 3mg either… I’d go back down to 1 and then ramp up… especially because you won’t know if they have side effects as you would for yourself. My IM vet advised this and it’s what most here advise for people, too, fwiw.
Research to help dogs live longer, healthier lives could unlock secrets for people to age better too
I. Executive Summary
The core thesis presented in the transcript centers on the Dog Aging Project (DAP) and the emergence of companion dogs as the primary high-fidelity model for human geroscience. Traditional longevity research suffers from a 90% translational failure rate when moving from murine (mouse) models to humans. The DAP seeks to bridge this “translational gap” by leveraging the shared environment (exposome), complex genetics, and compressed lifespans of domestic dogs to identify actionable interventions for age-related pathologies, specifically Cognitive Dysfunction Syndrome (CDS) and general senescence.
Key findings from the longitudinal study (n=50,000+) indicate that environmental variables—specifically social companionship and physical activity—are potent modifiers of healthspan. Dogs lacking regular exercise exhibit a six-fold increase in dementia risk. Pathologically, canine brains exhibit beta-amyloid plaques and microglial inflammation strikingly similar to human Alzheimer’s Disease, providing a more accurate substrate for pharmacological testing than transgenic rodents.
The pharmacological focus is currently on Rapamycin (Sirolimus), an mTOR inhibitor. While murine data suggests up to a 60% increase in lifespan, early-stage canine trials (TRIAD study) focus on cognitive preservation and inflammatory reduction. Results from pilot studies show a measurable decrease in teal-colored microglial cells (inflammatory markers) in Rapamycin-treated subjects. Simultaneously, the biotech startup Loyal is navigating the FDA’s conditional approval pathway for drugs targeting the IGF-1 pathway (LOY-001) and metabolic health (LOY-002), aiming for an incremental increase of one “healthy year” of life.
The consensus among the featured experts (Kaeberlein, McGrath, Keane) is that aging is a conserved biological process. By treating aging as a modifiable medical condition in dogs, the project aims to establish a regulatory and scientific precedent for human longevity therapeutics. However, significant knowledge gaps remain regarding long-term safety, optimal dosing, and the distinction between delayed senescence versus true lifespan extension in non-controlled environments.
II. Insight Bullets
The Murine Translational Gap: Approximately 90% of interventions successful in mice fail in human clinical trials, necessitating an intermediate, complex model like the companion dog.
Shared Exposome: Dogs share human environments, including water, air quality, and activity patterns, making them superior to lab-controlled animals for studying environmental impacts on longevity.
Accelerated Longitudinal Data: Canine lifespans compress 80 years of human aging into 10–15 years, allowing for rapid assessment of longevity interventions.
Social Determinants of Health: Longitudinal DAP data suggests that dogs living with other conspecifics (socialization) correlate with lower disease incidence.
Exercise and Neurodegeneration: A lack of physical exercise is associated with a 600% (6x) increase in the risk of developing canine dementia.
Neuropathological Homology: Canine dementia (CDS) presents with beta-amyloid plaques and brain atrophy (shrunken cortex, enlarged ventricles) nearly identical to human Alzheimer’s pathology.
Rapamycin Mechanism: Rapamycin functions by inhibiting the mTOR (mechanistic Target of Rapamycin) pathway, which regulates cell growth and protein synthesis.
Neuro-inflammatory Reduction: Pilot data indicates Rapamycin reduces microglial activation, the primary driver of neuro-inflammation in the aging brain.
FDA Regulatory Shift: The FDA has signaled a “reasonable expectation of effectiveness” for longevity drugs (Loyal), creating a new regulatory category for “aging” as a treatable condition.
IGF-1 Pathway Targeting: Loyal’s LOY-001 focuses on reducing the Insulin-like Growth Factor-1 (IGF-1) levels, particularly in large-breed dogs where high IGF-1 is linked to accelerated aging.
Public Data Access: The DAP maintains a public database for global researchers, accelerating the identification of longevity biomarkers across 50,000+ subjects.
Prevention vs. Rescue: Experts emphasize that longevity therapeutics are intended for preventative use (starting mid-life) rather than “deathbed” rescue missions.
Economic Viability: The canine longevity market is viewed as a multi-billion dollar proof-of-concept for eventual human application.
Biomarker Identification: MRI and blood sample analysis in the DAP are identifying early markers of cognitive decline before clinical symptoms manifest.
IV. Actionable Protocol (Prioritized)
High Confidence Tier (Level A/B Evidence)
Consistent Physical Activity: Implement daily exercise to mitigate neurodegeneration risks. In canine models, sedentary behavior is the strongest predictor of dementia Bray et al., 2022.
Social Integration: Maintain high levels of social interaction. Pro-social environments are correlated with lower morbidity in the DAP longitudinal cohort Levy et al., 2023.
Weight & Metabolic Management: Given the link between the IGF-1 pathway and aging, maintaining a lean body mass is a verified method to reduce the “rate of aging” Kealy et al., 2002.
Experimental Tier (Level C/D Evidence)
Rapamycin (Low-Dose/Intermittent): Based on the TRIAD pilot and murine data, low-dose Rapamycin may reduce neuro-inflammation.
IGF-1 Modulation: Targeting the growth hormone axis (via LOY-001 or similar mechanisms) to slow senescence in large-body phenotypes. Source unverified in live search for human longevity RCTs; canine data is in ongoing Phase 2/3 trials.
Red Flag Zone (Safety Data Absent)
Direct Translation of 60% Lifespan Extension: The “60% increase” cited in the transcript is based on mouse models. It is speculative and highly unlikely to translate to the same magnitude in humans or dogs.
Late-Stage Intervention: Longevity compounds are not “rescue” drugs. Administering these to subjects already in advanced failure/end-of-life provides zero confirmed benefit.